4.3 Article

Telemedicine Use for Movement Disorders: A Global Survey

Journal

TELEMEDICINE AND E-HEALTH
Volume 24, Issue 12, Pages 979-992

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/tmj.2017.0295

Keywords

telemedicine; geography; healthcare; movement disorders; technology; video

Funding

  1. Patient-Centered Outcomes Research Institute
  2. AbbVie
  3. AMC Health
  4. Burroughs Wellcome Fund
  5. Huntington Study Group
  6. Greater Rochester Health Foundation
  7. Michael J. Fox Foundation
  8. National Institute of Neurological Disorders and Stroke
  9. Roche
  10. Safra Foundation
  11. Teva Pharmaceuticals
  12. NIH
  13. Parkinson's Disease Foundation
  14. International Parkinson
  15. MDS
  16. Stichting Parkinson Fonds
  17. Topsector Life Sciences and Health
  18. UCB Pharma
  19. Pfizer
  20. NPF
  21. CHDI
  22. Teva
  23. Department of Defense
  24. Sage Bionetworks
  25. National Institutes of Health
  26. Neurocrine Biosciences
  27. Cynapsus Therapeutics
  28. Adamas Pharmaceuticals
  29. NIH/NINDS [5U01NS082133-05, 5P50NS03 8377-18]
  30. NIH/NIA [2R01AG038791]
  31. King Fahad Medical City, Riyadh, Saudi Arabia
  32. European Huntington's disease Registry
  33. International Parkinson's disease and Movement Disorder Society
  34. Allergan
  35. NIH/NINR
  36. Boston Scientific Corp.
  37. MJFF
  38. Great Lakes Neurotechnologies
  39. Medtronic

Ask authors/readers for more resources

Background:Telemedicine is increasingly used to care for patients with movement disorders, but data regarding its global use are limited.Introduction:To obtain baseline international data about telemedicine use among movement disorder clinicians.Methods:An online survey was sent to all 6,056 Movement Disorder Society members in 2015. Scope, reimbursement, and perceived quality of telemedicine were assessed.Results:There were 549 respondents (9.1% overall response rate) from 83 countries. Most (85.8%) were physicians, and most (70.9%) worked in an academic or university practice. Half of respondents (n=287, from 57 countries) used telemedicine for clinical care; activities included e-mail (63.2%), video visits (follow-up [39.7%] and new [35.2%]), and video-based education (35.2%). One hundred five respondents personally conducted video visits, most frequently to outpatient clinics (53.5%), patient homes (30.8%), and hospital inpatients (30.3%). The most common challenges were a limited neurological examination (58.9%) and technological difficulties (53.3%), and the most common benefits were reduced travel time (92.9%) and patient costs (60.1%). The most frequent reimbursements were none (39.0%), public insurance (24.5%), and patient payment (9.3%). Half of respondents planned to use telemedicine in the future, and three-quarters were interested in telemedicine education.Conclusions:More than 250 respondents around the world engage in telemedicine for movement disorders; most perceived benefit for patients, despite challenges and reimbursement for clinicians. Formal instruction on telemedicine is highly desired. Although the survey response was low and possibly biased to over represent those with telemedicine experience, the study provides baseline data for future comparison and to improve telemedicine delivery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available